KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

businesswire

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema – NEWSnet – News… as it used to be

More Press Releases

June 14, 2026

Matsato Introduces Two Chef’s Knife Designs Engineered for Different Cooks and Cutting Styles

June 14, 2026

Global Times: Discover Chinese coffee’s story of transformation in Yunnan

June 14, 2026

Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer

June 14, 2026

Global Times: ‘China’s rural revitalization is not only about large-scale infrastructure but small yet practical livelihood innovations’: US influencer